New advances in the treatments of drug-resistant tuberculosis

Mahmoud, M.; Tan, Yurong

doi:10.1080/14787210.2023.2240022

Cited by 4 publications

(1 citation statement)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Various types of NDDS-loaded anti-TB drugs, including nanoemulsions [ 240 ], lipid nanoparticles [ 241 ], metal-based nanoparticles [ 242 ], polymeric nanoparticles [ 240 ], and mesoporous silica nanoparticles [ 243 ]. These nanosystems have presented set of advantages and challenges towards the optimization of new approaches for TB treatment.…”

Section: Nanoscale Drug Delivery Systemsmentioning

confidence: 99%

Breaking barriers: The potential of nanosystems in antituberculosis therapy

Carnero Canales,

Marquez Cazorla,

Marquez Cazorla

et al. 2024

Bioactive Materials

View full text Add to dashboard Cite

Section: Nanoscale Drug Delivery Systemsmentioning

confidence: 99%

Breaking barriers: The potential of nanosystems in antituberculosis therapy

Carnero Canales,

Marquez Cazorla,

Marquez Cazorla

et al. 2024

Bioactive Materials

View full text Add to dashboard Cite

Application of CRISPR–cas-based technology for the identification of tuberculosis, drug discovery and vaccine development

Shi,

Gu,

Long

et al. 2024

Mol Biol Rep

View full text Add to dashboard Cite

Drug Selection and Posology, Optimal Therapies and Risk/Benefit Assessment in Medicine: The Paradigm of Iron-Chelating Drugs

Kontoghiorghes

2023

IJMS

View full text Add to dashboard Cite

The design of clinical protocols and the selection of drugs with appropriate posology are critical parameters for therapeutic outcomes. Optimal therapeutic protocols could ideally be designed in all diseases including for millions of patients affected by excess iron deposition (EID) toxicity based on personalised medicine parameters, as well as many variations and limitations. EID is an adverse prognostic factor for all diseases and especially for millions of chronically red-blood-cell-transfused patients. Differences in iron chelation therapy posology cause disappointing results in neurodegenerative diseases at low doses, but lifesaving outcomes in thalassemia major (TM) when using higher doses. In particular, the transformation of TM from a fatal to a chronic disease has been achieved using effective doses of oral deferiprone (L1), which improved compliance and cleared excess toxic iron from the heart associated with increased mortality in TM. Furthermore, effective L1 and L1/deferoxamine combination posology resulted in the complete elimination of EID and the maintenance of normal iron store levels in TM. The selection of effective chelation protocols has been monitored by MRI T2* diagnosis for EID levels in different organs. Millions of other iron-loaded patients with sickle cell anemia, myelodysplasia and haemopoietic stem cell transplantation, or non-iron-loaded categories with EID in different organs could also benefit from such chelation therapy advances. Drawbacks of chelation therapy include drug toxicity in some patients and also the wide use of suboptimal chelation protocols, resulting in ineffective therapies. Drug metabolic effects, and interactions with other metals, drugs and dietary molecules also affected iron chelation therapy. Drug selection and the identification of effective or optimal dose protocols are essential for positive therapeutic outcomes in the use of chelating drugs in TM and other iron-loaded and non-iron-loaded conditions, as well as general iron toxicity.

show abstract

New advances in the treatments of drug-resistant tuberculosis

Cited by 4 publications

References 63 publications

Breaking barriers: The potential of nanosystems in antituberculosis therapy

Breaking barriers: The potential of nanosystems in antituberculosis therapy

Application of CRISPR–cas-based technology for the identification of tuberculosis, drug discovery and vaccine development

Drug Selection and Posology, Optimal Therapies and Risk/Benefit Assessment in Medicine: The Paradigm of Iron-Chelating Drugs

Contact Info

Product

Resources

About